[ad_1]
A vial of the anti-Ebola drug Remdesivir is shown during a press conference at Eppendorf University Hospital (UKE) in Hamburg, Germany, as the spread of the coronavirus disease (COVID-19) continues. Ulrich Perrey / Pool via REUTERS – RC2E0G9B5B0X
The study was conducted by Shenzhen Maternity and Child Healthcare Hospital and Shenzhen Second People’s Hospital.
- News18.com
- Last update: April 26, 2020 5:16 PM IST
Carry off: Preliminary findings in a study by Chinese researchers revealed that the drug Gilead Sciences Inc. that was being tested as a possible treatment for COVID-19 may reduce sperm count in mice.
The study was conducted by Shenzhen Maternity and Child Healthcare Hospital and Shenzhen Second People’s Hospital. The preliminary findings were revealed after 28 male mice were injected with the antiviral drug remdesivir.
The injected mice showed a downward trend in their sperm count and motility, at the same time, an increase in the number of sperm abnormalities was also observed. However, the results have not yet been peer reviewed.
A Bloomberg report mentions that the study was published on the biology preprint website on April 23, operated primarily by Cold Spring Harbor Laboratory.
For the second time in a week, the drug remdesivir, which was closely watched, has made world news. Previously, remdesivir lowered expectations after its first randomized human trial failed Thursday. However, Gilead Sciences released a statement Friday questioning reports that its antiviral drug remdesivir was found to be ineffective as a treatment for COVID-19.
